Skin DiseasesNCT07341906
Diagnosis Evaluation Made by Artificial Inteligence in Response to a Request Made by General Praticioner on OMNIDOC to the Dermatologist of the CHU of Nice. A Comparison of This Response by the One Made by the Dermatologist.
An observational study of Skin Diseases and Artificial Intelligence, run by Centre Hospitalier Universitaire de Nice at 1 site in France.
Trial summary
The First part of the study will be the inclusion of our patients (those for whom a tele-expertise request has been made by their general practitioner on the OMNIDOC platform between the 1st of May 2024 and the 31st of December 2025. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Skin Diseases, Artificial Intelligence
- What is being tested?
- The diagnosis made by Chat Gpt
- How many people
- 1,000 participants
- Where
- 1 siteFrance
- Study dates
- 1 Jan 2026to 30 Jun 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patient for whom a tele-expertise request has ben made by their general practitioner on the OMNIDOC platform between the 1st of May 2024 and the 31st of December 2025.
Who may be able to join
- Adult with a request on OMNIDOC made by their general practitioner.
- Adult not opposed Social Security affiliation.
- Diagnosis made by a dermatologist.
Who cannot join
- Pediatric case.
- Unusable image.
- Absence of diagnosis made by a dermatologist.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Evaluation of the Contribution of Artificiel Inteligence on a Dermatologist Tele -Expertise Request Made by General Praticioner : a Retrospective and Single-center Study.
The First part of the study will be the inclusion of our patients (those for whom a tele-expertise request has been made by their general practitioner on the OMNIDOC platform between the 1st of May 2024 and the 31st of December 2025. ) After that, the team will investigate the non opposition patient to the use of their personal information.
Subsequently, the clinical study will focus on comparing the diagnosis made by chat gpt expert and a dermatologist from the University Hospital of Nice to a request of dermatology tele-expertise made by general praticioner on OMNIDOC
- Conditions
- Skin Diseases, Artificial Intelligence
- Being tested
- The diagnosis made by Chat Gpt
- Medical subject headings
- Skin Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
The diagnosis made by Chat GptOther
The expert had provided a diagnosis and a support based on the guideline in France
| Study group | Role | What they receive |
|---|---|---|
| Expert opinion | The expert had provided a diagnosis and a support based on the guideline in France Receives: Other: The diagnosis made by Chat Gpt | |
| chatGPT opinion | ChatGPT will provide a diagnosis and the support based on the guideline in France Receives: Other: The diagnosis made by Chat Gpt | |
| Specialized AI opinion | Specialised IA will provide a diagnosis and the support based on the guideline in France Receives: Other: The diagnosis made by Chat Gpt |
What is being measured
The primary outcome is the main question the study is designed to answer.
Compare the diagnoses offered by artificial intelligence to those proposed by the experts on requests for tele-expertise.
Check the correspondence between the diagnosis made by the expert and the artificial intelligence on the photos, the diagnosis and supports.
Measured: From 01 May 2025 - 31 December 2026
Secondary outcomes (2)
Compare the support and response times offered by artificial intelligence to those offered by experts for dermatology tele-expertise requests.
Check the consistency between the expert's instructions and the timeframe for intervention, and the information provided by the two artifical intelligence by The photos, the diagnosis and supports
Measured: From 01 May 2025 - 31 December 2026
Compare the differences between the responses offered by chatGPT and the specific dermatologic artificial intelligence
Compare the differences between the responses offered by chatGPT and the specific dermatologic artificial intelligence by the photos, the diagnosis and supports
Measured: From 01 May 2025 - 31 December 2026
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jan 2026
- Study start1 Jan 2026 (estimated)
- Primary completion30 Jun 2026 (estimated)
- Study completion30 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Skin DiseasesStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire de NiceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire de Nice
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07341906
- Sponsor's protocol ID
- 25MedInterne01
- Status last verified
- Dec 2025
- First submitted
- 24 Dec 2025
- Last updated
- 14 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Contribution of Artificiel Inteligence on a Dermatologist Tele -Expertise Request Made by General Praticioner : a Retrospective and Single-center Study.
- ClinicalTrials.gov ID
- NCT07341906
- Acronym / sponsor ID
- 25MedInterne01
- Conditions
- Skin Diseases, Artificial Intelligence
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire de NiceUniversity, hospital or other
- Study start
- 1 Jan 2026 (estimated)
- Primary completion
- 30 Jun 2026 (estimated)
- Study completion
- 30 Jun 2026 (estimated)
- First posted
- 14 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The First part of the study will be the inclusion of our patients (those for whom a tele-expertise request has been made by their general practitioner on the OMNIDOC platform between the 1st of May 2024 and the 31st of December 2025. ) After that, the team will investigate the non opposition patient to the use of their personal information.
Subsequently, the clinical study will focus on comparing the diagnosis made by chat gpt expert and a dermatologist from the University Hospital of Nice to a request of dermatology tele-expertise made by general praticioner on OMNIDOC
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Expert opinion | – | Other: The diagnosis made by Chat GptThe expert had provided a diagnosis and a support based on the guideline in France |
| chatGPT opinion | – | Other: The diagnosis made by Chat GptChatGPT will provide a diagnosis and the support based on the guideline in France |
| Specialized AI opinion | – | Other: The diagnosis made by Chat GptSpecialised IA will provide a diagnosis and the support based on the guideline in France |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patient for whom a tele-expertise request has ben made by their general practitioner on the OMNIDOC platform between the 1st of May 2024 and the 31st of December 2025.
Key inclusion criteria (3 listed)
- Adult with a request on OMNIDOC made by their general practitioner.
- Adult not opposed Social Security affiliation.
- Diagnosis made by a dermatologist.
Key exclusion criteria (3 listed)
- Pediatric case.
- Unusable image.
- Absence of diagnosis made by a dermatologist.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| The diagnosis made by Chat GptThe expert had provided a diagnosis and a support based on the guideline in France | Other | Expert opinion, Specialized AI opinion, chatGPT opinion |
Primary outcome
Compare the diagnoses offered by artificial intelligence to those proposed by the experts on requests for tele-expertise.
Time frame: From 01 May 2025 - 31 December 2026
Check the correspondence between the diagnosis made by the expert and the artificial intelligence on the photos, the diagnosis and supports.
2 secondary outcomes
Compare the support and response times offered by artificial intelligence to those offered by experts for dermatology tele-expertise requests.
Time frame: From 01 May 2025 - 31 December 2026
Compare the differences between the responses offered by chatGPT and the specific dermatologic artificial intelligence
Time frame: From 01 May 2025 - 31 December 2026
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jan 2026.
Related trials for Skin Diseases
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 3
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Breast Cancer
Not yet recruitingPhase 1
Safety and Biodistribution of [68Ga]Ga DOTA-5G in Subjects With Metastatic Breast Cancer (BC)
Metastatic Breast Cancer
Active, not recruiting
Peer Navigator Education in Improving Survivorship Care in African American Breast Cancer Survivors
Breast Cancer
RecruitingObservational study
Improved Facial Skin Quality and Quality of Life After VYC-12L Treatment in Breast Cancer Survivors
Quality of Life, Breast Neoplasms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Skin Diseases and Artificial Intelligence, run by Centre Hospitalier Universitaire de Nice at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 14 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Compare the diagnoses offered by artificial intelligence to those proposed by the experts on requests for tele-expertise. (time frame: From 01 May 2025 - 31 December 2026). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jan 2026.